Business Wire

MI-EATON

8.9.2022 12:31:47 CEST | Business Wire | Press release

Share
Eaton to showcase innovative electrified commercial vehicle technologies at IAA Transportation show

Power management company Eaton will display technologies to support the zero emissions journey in the commercial vehicle market Sept. 20-25 at the IAA Transportation show in Hannover, Germany.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220908005014/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Eaton’s eMobility business provides electrified vehicle solutions for its global commercial vehicle customers. (Photo: Business Wire)

“We are helping our customers around the globe with technologies that solve some of the toughest challenges throughout the electrified vehicle (EV) ecosystem,” said Scott Adams, president, Eaton’s eMobility business. “Eaton provides a vast portfolio of EV technologies for full battery electric, fuel cell and hybrid commercial vehicles, as well as EV charging infrastructure solutions.”

Flex Power Distribution Unit delivers safe power for commercial electrified vehicles

Eaton’s eMobility business offers a new Flex Power Distribution Unit (PDU) for high-voltage electrified commercial vehicles that is uniquely designed to handle multiple load requirements.

The Flex PDU integrates Eaton’s Breaktor® circuit protection technology, which improves vehicle safety and protects components from any level of overcurrent condition more effectively than traditional circuit protection methods. The Breaktor circuit protection solution is resettable like a circuit breaker, enabling reactivation of the device following a functionality check and reducing cost for both the OEM and consumer.

The Flex PDU also leverages sealed and corrosion-resistant terminals and connectors from Royal Power Solutions, a global leader in power distribution and transmission solutions that Eaton acquired earlier this year. Eaton’s Bussmann® series fuses are also integrated to meet the requirements for use in the latest high-powered electrified vehicles with ratings up to 1,000 volts of direct current (VDC) and 600 amps.

Eaton’s Flex PDU protects vital components and occupants and is also an intelligent unit that provides the OEM diagnostic information, including where the most power is being consumed, to maximize performance and efficiency. Its integrated and optimized design reduces the number of components, lessening complexity.

Electrified vehicle transmissions, gearing improves performance, range

Eaton’s new 4-speed transmissions provide superior performance on grades and acceleration for electrified commercial vehicles while offering more flexible gear ratios compared to competitive technologies. The compact 4-speed transmissions for medium- and heavy-duty electrified commercial vehicles also improve system efficiency, enabling longer vehicle range and battery life.

“We supply transmissions for multiple global commercial vehicle manufacturers, and many more are interested,” Adams said. “With decades of experience, we continue to build on our heritage as a top supplier of commercial vehicle transmissions.”

DC-DC converters available in a range of power configurations

Eaton recently introduced a 48-volt DC-DC converter to power accessories such as antilock brakes and lighting for commercial vehicles with 48-volt electrical systems. Unlike competitive offerings, Eaton’s DC-DC converters are operational in ambient temperatures up to 85 degrees Celsius and boast 97% design efficiency.

Eaton’s DC-DC converter portfolio covers a spectrum of power requirements, ranging from low- to high-voltage systems, depending on customer specifications. The converters can be tuned for particular duty cycles via their advanced digital control architecture, enabling flexible control modes through firmware adaptation.

Green Motion acquisition bolsters Eaton’s vehicle charging capabilities

In March 2021, Eaton acquired Switzerland-based Green Motion SA, a leading designer and manufacturer of electric vehicle charging hardware and related software. Eaton’s efficient electric vehicle charging infrastructure expertise includes the production and operation of charging stations, designing management software for charging networks, and serving as an electric mobility service provider.

‘Buildings as a Grid’ strategy expands charging possibilities

Many workplaces host vehicle fleets, such as cars for the salesforce and vans for deliveries. Fleet managers switching to EVs, either now or in the future, will want to electrify their fleet while ensuring business continuity. Eaton’s “Buildings as a Grid” approach helps fleet managers devise an EV charging strategy that is fast to implement, cybersecure and scalable so that they can add more EV charging capacity when needed.

The strategy may include EV charging infrastructure at their site or depot, on-site renewables like solar panels on buildings, and options for fleet drivers to charge at home and when they are traveling. Eaton’s digital and physical infrastructure transforms a workplace or depot into an energy hub, and because it is a gateway to electrifying the entire functionality of the site, it is also an investment in the energy transition.

Eaton is an intelligent power management company dedicated to improving the quality of life and protecting the environment for people everywhere. Eaton is guided by its commitment to do business right, operate sustainably, and to help its customers manage power ─ today and well into the future. By capitalizing on the global growth trends of electrification and digitalization, Eaton is accelerating the planet’s transition to renewable energy, helping to solve the world’s most urgent power management challenges, and doing what’s best for its stakeholders and all of society.

Founded in 1911, Eaton has been listed on the NYSE for nearly a century. We reported revenues of $19.6 billion in 2021 and serve customers in more than 170 countries. For more information, visit www.eaton.com. Follow us on Twitter and LinkedIn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220908005014/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye